Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry

被引:15
|
作者
Matsuo, Ryu [1 ,2 ]
Kamouchi, Masahiro [2 ,3 ]
Fukuda, Haruhisa [2 ,3 ]
Hata, Jun [1 ,3 ]
Wakisaka, Yoshinobu [1 ]
Kuroda, Junya [1 ]
Ago, Tetsuro [1 ]
Kitazono, Takanari [1 ,3 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka 812, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Ctr Cohort Studies, Fukuoka 812, Japan
来源
PLOS ONE | 2014年 / 9卷 / 10期
关键词
RT-PA; TRIAL IST-3; MANAGEMENT; GREATER-THAN-OR-EQUAL-TO-80; ALTEPLASE; TPA;
D O I
10.1371/journal.pone.0110444
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. Methods: Of 13,521 stroke patients registered in the Fukuoka Stroke Registry in Japan from June 1999 to February 2013, 953 ischemic stroke patients who were over 80 years old, hospitalized within 3 h of onset, and not treated with endovascular therapy were included in this study. Among them, 153 patients were treated with intravenous rt-PA (0.6 mg/kg). For propensity score (PS)-matched case-control analysis, 148 patients treated with rt-PA and 148 PS-matched patients without rt-PA therapy were selected by 1:1 matching with propensity for using rt-PA. Clinical outcomes were neurological improvement, good functional outcome at discharge, in-hospital mortality, and hemorrhagic complications (any intracranial hemorrhage [ICH], symptomatic ICH, and gastrointestinal bleeding). Results: In the full cohort of 953 patients, rt-PA use was associated positively with neurological improvement and good functional outcome, and negatively with in-hospital mortality after adjustment for multiple confounding factors. In PS-matched case-control analysis, patients treated with rt-PA were still at lower risk for unfavorable clinical outcomes than non-treated patients (neurological improvement, odds ratio 2.67, 95% confidence interval 1.61-4.40; good functional outcome, odds ratio 2.23, 95% confidence interval 1.16-4.29; in-hospital mortality, odds ratio 0.30, 95% confidence interval 0.13-0.65). There was no significant association between rt-PA use and risk of hemorrhagic complications in the full and PS-matched cohorts. Conclusions: Intravenous rt-PA therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged. 80 years) with acute ischemic stroke.
引用
收藏
页数:7
相关论文
共 50 条
  • [11] Outcomes of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Patients Aged 90 Years or Older
    Mateen, Farrah J.
    Nasser, Majeed
    Spencer, Byron R.
    Freeman, William D.
    Shuaib, Ashfaq
    Demaerschalk, Bart M.
    Wijdicks, Eelco F. M.
    MAYO CLINIC PROCEEDINGS, 2009, 84 (04) : 334 - 338
  • [12] Thrombolysis for acute ischemic stroke with recombinant tissue plasminogen activator in a Chilean public hospital
    Figueroa-Reyes, Tatiana
    Saez M, David
    Mansilla L, Eloy
    Sanchez, Rodrigo, V
    Nogales-Gaete, Jorge
    Delgado B, Iris
    REVISTA MEDICA DE CHILE, 2011, 139 (09) : 1118 - 1127
  • [13] A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset
    Balogun, Ibrahim O.
    Brown, Aaron
    Bertoni, Miguel
    Webb, Thomas
    Hargroves, David
    Pullicino, Patrick
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2016, 25 (08) : 1843 - 1850
  • [14] Analysis of the Efficacy and Safety of Recombinant Tissue Plasminogen Activator for Chinese Patients over 80 Years of Age with Acute Ischemic Stroke: A Pilot Study
    Yang, Jiandao
    Liang, Huazheng
    Song, Yanyan
    Shen, Lingda
    Wang, Shaoshi
    NEUROSCIENCE BULLETIN, 2016, 32 (02) : 202 - 203
  • [15] In-hospital outcomes of intravenous recombinant tissue plasminogen activator treatment for acute ischemic stroke in patients aged >80 years: Findings from the Chinese Stroke Center Alliance
    Jiang, Yingyu
    Wang, Chunjuan
    Gu, Hongqiu
    Zhou, Qi
    Jiang, Yong
    Li, Zixiao
    Wang, Yongjun
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2025, 34 (01)
  • [16] Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
    Sadeghi-Hokmabadi, Elyar
    Farhoudi, Mehdi
    Taheraghdam, Aliakbar
    Hashemilar, Mazyar
    Savadi-Osguei, Daryous
    Rikhtegar, Reza
    Mehrvar, Kaveh
    Sharifipour, Ehsan
    Youhanaee, Parisa
    Mirnour, Reshad
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2016, 9 : 361 - 367
  • [17] Association of Admission Leukocyte Count with Clinical Outcomes in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator
    Chen, Jie
    Zhang, Fu-Liang
    Lv, Shan
    Jin, Hang
    Luo, Yun
    Qu, Yang
    Guo, Zhen-Ni
    Yang, Yi
    CURRENT NEUROVASCULAR RESEARCH, 2021, 17 (05) : 660 - 666
  • [18] Symptomatic Intracerebral Hemorrhage in Acute Ischemic Stroke After Thrombolysis With Intravenous Recombinant Tissue Plasminogen Activator A Review of Natural History and Treatment
    Yaghi, Shadi
    Eisenberger, Andrew
    Willey, Joshua Z.
    JAMA NEUROLOGY, 2014, 71 (09) : 1181 - 1185
  • [19] Systemic thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: first Croatian experiences
    Vesna Matijević
    Domagoj Alvir
    Branko Malojčić
    Lea Unušić
    Svjetlana Šupe
    Marina Boban
    Andrea Bujan-Kovač
    Mario Habek
    Zdravka Poljaković
    Neurological Sciences, 2010, 31 : 693 - 697
  • [20] Repeated Intravenous Treatment with Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Ischemic Stroke
    Laible, Mona
    Jenetzky, Ekkehardt
    Moehlenbruch, Markus
    Ringleb, Peter Arthur
    Rizos, Timolaos
    EUROPEAN NEUROLOGY, 2015, 74 (3-4) : 127 - 134